Page last updated: 2024-10-28
1-(5-isoquinolinesulfonyl)-2-methylpiperazine and Angina Pectoris with Normal Coronary Arteriogram
1-(5-isoquinolinesulfonyl)-2-methylpiperazine has been researched along with Angina Pectoris with Normal Coronary Arteriogram in 1 studies
1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine: A specific protein kinase C inhibitor, which inhibits superoxide release from human neutrophils (PMN) stimulated with phorbol myristate acetate or synthetic diacylglycerol.
1-(5-isoquinolinesulfonyl)-2-methylpiperazine : A member of the class of N-sulfonylpiperazines that is 2-methylpiperazine substituted at position 1 by a 5-isoquinolinesulfonyl group.
Research Excerpts
| Excerpt | Relevance | Reference |
|---|
| "We sought to determine whether a potent Rho-kinase inhibitor fasudil prevents the occurrence of myocardial ischemia in patients with microvascular angina attributable to coronary microvascular spasm." | 9.10 | Rho-kinase inhibition with intracoronary fasudil prevents myocardial ischemia in patients with coronary microvascular spasm. ( Hirakawa, Y; Masumoto, A; Mohri, M; Shimokawa, H; Takeshita, A, 2003) |
| "We sought to determine whether a potent Rho-kinase inhibitor fasudil prevents the occurrence of myocardial ischemia in patients with microvascular angina attributable to coronary microvascular spasm." | 5.10 | Rho-kinase inhibition with intracoronary fasudil prevents myocardial ischemia in patients with coronary microvascular spasm. ( Hirakawa, Y; Masumoto, A; Mohri, M; Shimokawa, H; Takeshita, A, 2003) |
Research
Studies (1)
| Timeframe | Studies, this research(%) | All Research% |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|
| Mohri, M | 1 |
| Shimokawa, H | 1 |
| Hirakawa, Y | 1 |
| Masumoto, A | 1 |
| Takeshita, A | 1 |
Clinical Trials (1)
Trial Overview
| Trial | Phase | Enrollment | Study Type | Start Date | Status |
|---|
| Pilot Study of Telmisartan (Micardis) For the Prevention of Acute Graft vs. Host Disease Post Allogeneic Hematopoietic Stem Cell Transplantation[NCT02338232] | | 32 participants (Actual) | Interventional | 2015-07-07 | Terminated (stopped due to Lack of Accrual) |
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Trials
1 trial available for 1-(5-isoquinolinesulfonyl)-2-methylpiperazine and Angina Pectoris with Normal Coronary Arteriogram